Allergan board unanimously rebuffs latest acquisition offer from Valeant, Pershing Square
Allergan's board is unanimously rejecting the latest takeover bid from Valeant Pharmaceuticals, and the Botox maker says the offer isn't even worth talking about.
Allergan says a May 30 offer from the Canadian drugmaker and activist investor Bill Ackman's Pershing Square Capital Management still substantially undervalues Allergan Inc. and creates too much risk for shareholders. Allergan also says the deal doesn't offer enough value to warrant discussions between the companies.
That deal amounts to around $53 billion. It includes $72 in cash and a portion of Valeant Pharmaceuticals International Inc. stock for each Allergan share and was up from a previous bid that involved $58.30 in cash and the stock portion.
Ackman is a big Allergan shareholder. He has said he will move to replace most of Allergan's board.
Read more Business News
- BC chief's pay, expenses: $1MBC
- Swimmer's body foundVernon / N. Okanagan
- Body & truck pulled from riverVernon / N. Okanagan
- Pickup hit and runKelowna
|QHR Technologies Inc||1.17||-0.04|
|Anavex Life Sciences||0.26||-0.002|
|Copper Mountain Mining||2.72||-0.03|
|Sunrise Resources Ltd||0.03||-0.005|
|Mission Ready Services||0.15||0.00|
On March 6, 2010 a bridge in Turku, Finland bent 56 inches (143 centimeters) due to structural failures of both piers. No one was injured. The bridge had to be demolished 4 months later. Our infrast...
Eighty percent of our success in learning from other people is based on how well we listen. Other people’s experience can be enormously helpful. With it we can often overcome time restraints and...
Photo: Thinkstock.comWays to reduce your Debt:Make a budget and get budget counselingA basic first step for debt reduction is to prepare a budget and plan your spending. Once you have a budget, you mu...